Literature DB >> 33802562

VTRNA2-1: Genetic Variation, Heritable Methylation and Disease Association.

Pierre-Antoine Dugué1,2,3, Chenglong Yu1, Timothy McKay1, Ee Ming Wong1, Jihoon Eric Joo4, Helen Tsimiklis1, Fleur Hammet1, Maryam Mahmoodi1, Derrick Theys1, John L Hopper3, Graham G Giles1,2,3, Roger L Milne1,2,3, Jason A Steen1, James G Dowty3, Tu Nguyen-Dumont1,4, Melissa C Southey1,2,4.   

Abstract

VTRNA2-1 is a metastable epiallele with accumulating evidence that methylation at this region is heritable, modifiable and associated with disease including risk and progression of cancer. This study investigated the influence of genetic variation and other factors such as age and adult lifestyle on blood DNA methylation in this region. We first sequenced the VTRNA2-1 gene region in multiple-case breast cancer families in which VTRNA2-1 methylation was identified as heritable and associated with breast cancer risk. Methylation quantitative trait loci (mQTL) were investigated using a prospective cohort study (4500 participants with genotyping and methylation data). The cis-mQTL analysis (334 variants ± 50 kb of the most heritable CpG site) identified 43 variants associated with VTRNA2-1 methylation (p < 1.5 × 10-4); however, these explained little of the methylation variation (R2 < 0.5% for each of these variants). No genetic variants elsewhere in the genome were found to strongly influence VTRNA2-1 methylation. SNP-based heritability estimates were consistent with the mQTL findings (h2 = 0, 95%CI: -0.14 to 0.14). We found no evidence that age, sex, country of birth, smoking, body mass index, alcohol consumption or diet influenced blood DNA methylation at VTRNA2-1. Genetic factors and adult lifestyle play a minimal role in explaining methylation variability at the heritable VTRNA2-1 cluster.

Entities:  

Keywords:  MIR886; SNP-based heritability; VTRNA2-1; breast cancer; methylation quantitative trait loci; nc886; prostate cancer; rs2346018

Mesh:

Substances:

Year:  2021        PMID: 33802562      PMCID: PMC7961504          DOI: 10.3390/ijms22052535

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  65 in total

1.  Allelic methylation levels of the noncoding VTRNA2-1 located on chromosome 5q31.1 predict outcome in AML.

Authors:  Marianne Bach Treppendahl; Xiangning Qiu; Alexandra Søgaard; Xiaojing Yang; Cecilie Nandrup-Bus; Christoffer Hother; Mette Klarskov Andersen; Lars Kjeldsen; Lars Möllgård; Lars Möllgaard; Eva Hellström-Lindberg; Johan Jendholm; Bo T Porse; Peter A Jones; Gangning Liang; Kirsten Grønbæk
Journal:  Blood       Date:  2011-11-04       Impact factor: 22.113

2.  Novel associations between blood DNA methylation and body mass index in middle-aged and older adults.

Authors:  Y M Geurts; P-A Dugué; J E Joo; E Makalic; C-H Jung; W Guan; S Nguyen; M L Grove; E M Wong; A M Hodge; J K Bassett; L M FitzGerald; H Tsimiklis; L Baglietto; G Severi; D F Schmidt; D D Buchanan; R J MacInnis; J L Hopper; J S Pankow; E W Demerath; M C Southey; G G Giles; D R English; R L Milne
Journal:  Int J Obes (Lond)       Date:  2017-10-16       Impact factor: 5.095

3.  Alternative dietary indices both strongly predict risk of chronic disease.

Authors:  Stephanie E Chiuve; Teresa T Fung; Eric B Rimm; Frank B Hu; Marjorie L McCullough; Molin Wang; Meir J Stampfer; Walter C Willett
Journal:  J Nutr       Date:  2012-04-18       Impact factor: 4.798

4.  Next-generation genotype imputation service and methods.

Authors:  Sayantan Das; Lukas Forer; Sebastian Schönherr; Carlo Sidore; Adam E Locke; Alan Kwong; Scott I Vrieze; Emily Y Chew; Shawn Levy; Matt McGue; David Schlessinger; Dwight Stambolian; Po-Ru Loh; William G Iacono; Anand Swaroop; Laura J Scott; Francesco Cucca; Florian Kronenberg; Michael Boehnke; Gonçalo R Abecasis; Christian Fuchsberger
Journal:  Nat Genet       Date:  2016-08-29       Impact factor: 38.330

5.  DNA methylation-mediated repression of miR-886-3p predicts poor outcome of human small cell lung cancer.

Authors:  Jianzhong Cao; Yongmei Song; Nan Bi; Jie Shen; Wenyang Liu; Jing Fan; Guogui Sun; Tong Tong; Jie He; Yuankai Shi; Xun Zhang; Ning Lu; Yinghua He; Hongyu Zhang; Kelong Ma; Xiaoying Luo; Lei Lv; Hui Deng; Jing Cheng; Jingde Zhu; Luhua Wang; Qimin Zhan
Journal:  Cancer Res       Date:  2013-04-16       Impact factor: 12.701

6.  Independent genomewide screens identify the tumor suppressor VTRNA2-1 as a human epiallele responsive to periconceptional environment.

Authors:  Matt J Silver; Noah J Kessler; Branwen J Hennig; Paula Dominguez-Salas; Eleonora Laritsky; Maria S Baker; Cristian Coarfa; Hector Hernandez-Vargas; Jovita M Castelino; Michael N Routledge; Yun Yun Gong; Zdenko Herceg; Yong Sun Lee; Kwanbok Lee; Sophie E Moore; Anthony J Fulford; Andrew M Prentice; Robert A Waterland
Journal:  Genome Biol       Date:  2015-06-11       Impact factor: 13.583

7.  Human noncoding RNA 886 (nc886) adopts two structurally distinct conformers that are functionally opposing regulators of PKR.

Authors:  Brenda M Calderon; Graeme L Conn
Journal:  RNA       Date:  2017-01-09       Impact factor: 4.942

Review 8.  The OncoArray Consortium: A Network for Understanding the Genetic Architecture of Common Cancers.

Authors:  Christopher I Amos; Joe Dennis; Zhaoming Wang; Jinyoung Byun; Fredrick R Schumacher; Simon A Gayther; Graham Casey; David J Hunter; Thomas A Sellers; Stephen B Gruber; Alison M Dunning; Kyriaki Michailidou; Laura Fachal; Kimberly Doheny; Amanda B Spurdle; Yafang Li; Xiangjun Xiao; Jane Romm; Elizabeth Pugh; Gerhard A Coetzee; Dennis J Hazelett; Stig E Bojesen; Charlisse Caga-Anan; Christopher A Haiman; Ahsan Kamal; Craig Luccarini; Daniel Tessier; Daniel Vincent; François Bacot; David J Van Den Berg; Stefanie Nelson; Stephen Demetriades; David E Goldgar; Fergus J Couch; Judith L Forman; Graham G Giles; David V Conti; Heike Bickeböller; Angela Risch; Melanie Waldenberger; Irene Brüske-Hohlfeld; Belynda D Hicks; Hua Ling; Lesley McGuffog; Andrew Lee; Karoline Kuchenbaecker; Penny Soucy; Judith Manz; Julie M Cunningham; Katja Butterbach; Zsofia Kote-Jarai; Peter Kraft; Liesel FitzGerald; Sara Lindström; Marcia Adams; James D McKay; Catherine M Phelan; Sara Benlloch; Linda E Kelemen; Paul Brennan; Marjorie Riggan; Tracy A O'Mara; Hongbing Shen; Yongyong Shi; Deborah J Thompson; Marc T Goodman; Sune F Nielsen; Andrew Berchuck; Sylvie Laboissiere; Stephanie L Schmit; Tameka Shelford; Christopher K Edlund; Jack A Taylor; John K Field; Sue K Park; Kenneth Offit; Mads Thomassen; Rita Schmutzler; Laura Ottini; Rayjean J Hung; Jonathan Marchini; Ali Amin Al Olama; Ulrike Peters; Rosalind A Eeles; Michael F Seldin; Elizabeth Gillanders; Daniela Seminara; Antonis C Antoniou; Paul D P Pharoah; Georgia Chenevix-Trench; Stephen J Chanock; Jacques Simard; Douglas F Easton
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-10-03       Impact factor: 4.254

9.  DNA methylation arrays as surrogate measures of cell mixture distribution.

Authors:  Eugene Andres Houseman; William P Accomando; Devin C Koestler; Brock C Christensen; Carmen J Marsit; Heather H Nelson; John K Wiencke; Karl T Kelsey
Journal:  BMC Bioinformatics       Date:  2012-05-08       Impact factor: 3.169

10.  nc886, a non-coding RNA and suppressor of PKR, exerts an oncogenic function in thyroid cancer.

Authors:  Eun Kyung Lee; Seung-Hyun Hong; Sooyong Shin; Hyun-Sung Lee; Ju-Seog Lee; Eun Jung Park; Sun Shim Choi; Jae Woong Min; Daeyoon Park; Jung-Ah Hwang; Betty H Johnson; Sung Ho Jeon; In-Hoo Kim; Yeon-Su Lee; Yong Sun Lee
Journal:  Oncotarget       Date:  2016-11-15
View more
  2 in total

1.  Methylation status of nc886 epiallele reflects periconceptional conditions and is associated with glucose metabolism through nc886 RNAs.

Authors:  Saara Marttila; Leena E Viiri; Pashupati P Mishra; Brigitte Kühnel; Pamela R Matias-Garcia; Leo-Pekka Lyytikäinen; Tiina Ceder; Nina Mononen; Wolfgang Rathmann; Juliane Winkelmann; Annette Peters; Mika Kähönen; Nina Hutri-Kähönen; Markus Juonala; Katriina Aalto-Setälä; Olli Raitakari; Terho Lehtimäki; Melanie Waldenberger; Emma Raitoharju
Journal:  Clin Epigenetics       Date:  2021-07-22       Impact factor: 6.551

2.  Association of FOXO3 Blood DNA Methylation with Cancer Risk, Cancer Survival, and Mortality.

Authors:  Chenglong Yu; Allison M Hodge; Ee Ming Wong; Jihoon Eric Joo; Enes Makalic; Daniel Schmidt; Daniel D Buchanan; John L Hopper; Graham G Giles; Melissa C Southey; Pierre-Antoine Dugué
Journal:  Cells       Date:  2021-12-01       Impact factor: 6.600

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.